Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.43 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24811561 | 0.85 | EGFR (0.41) | EGFRLRRK2HRH4 | |
| SCHEMBL13279450 | 0.81 | USP30 (0.47) | OPRD1GRIN2DGRIN3BCHRM1ADRA1D | |
| SCHEMBL18284854 | 0.81 | GRIN2D (0.49) | OPRD1GRIN2DGRIN3BCHRM1ADRA1D | |
| SCHEMBL18284820 | 0.81 | GRIN2D (0.49) | OPRD1GRIN2DGRIN3BCHRM1ADRA1D | |
| SCHEMBL16374375 | 0.77 | EGFR (0.50) | EGFR | |
| SCHEMBL22464585 | 0.77 | EGFR (0.50) | EGFR | |
| SCHEMBL19015477 | 0.77 | EGFR (0.50) | EGFR | |
| SCHEMBL15740505 | 0.77 | EGFR (0.50) | EGFR | |
| SCHEMBL15740731 | 0.77 | EGFR (0.50) | EGFR | |
| SCHEMBL30733190 | 0.77 | EGFR (0.50) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345329-A1 | HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF | VORONOI INC (KR) | 2025-11-13 | — | — | US | disclosed |
| EP-4534532-A1 | HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF | Voronoi Inc. (KR) | 2025-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345329-A1 | HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF | EGFR, ERBB2, ERBB3 | OPRD1 2231/4885EGFR 1/4885GRIN2D 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.